Molecular Mechanisms of Fibrosis-Associated Promotion of Liver Carcinogenesis by Uehara, Takeki et al.
© The Author 2013. Published by Oxford University Press on behalf of the Society of Toxicology. 
All rights reserved. For permissions, please email: journals.permissions@oup.com
Molecular Mechanisms of Fibrosis-Associated Promotion  
of Liver Carcinogenesis
Takeki Uehara,*,1 Garrett R. Ainslie,* Kristi Kutanzi,† Igor P. Pogribny,† Levan Muskhelishvili,† Takeshi Izawa,‡  
Jyoji Yamate,‡ Oksana Kosyk,* Svitlana Shymonyak,* Blair U. Bradford,* Gary A. Boorman,§ Ramon Bataller,¶ and Ivan Rusyn*,2
*Department of Environmental Sciences and Engineering, University of North Carolina, Chapel Hill, North Carolina; †National Center for Toxicological 
Research, U.S. FDA, Jefferson, Arkansas; ‡Department of Veterinary Pathology, Osaka Prefecture University, Osaka, Japan; §Covance, Chantilly, Virginia; 
and ¶Department of Nutrition, University of North Carolina, Chapel Hill, North Carolina
1Present address: Shionogi & Co., Ltd., Toyonaka, Osaka, Japan.
2To whom correspondence should be addressed at Department of Environmental Sciences and Engineering, University of North Carolina, Chapel Hill, NC 
27599-7431. Fax: +1-919-843-2596. E-mail: iir@unc.edu.
Received November 18, 2012; accepted December 12, 2012
Hepatocellular carcinoma (HCC) mostly develops in patients 
with advanced fibrosis; however, the mechanisms of interaction 
between a genotoxic insult and fibrogenesis are not well under-
stood. This study tested a hypothesis that fibrosis promotes HCC 
via a mechanism that involves activation of liver stem cells. First, 
B6C3F1 mice were administered diethylnitrosamine (DEN; single 
ip injection of 1 mg/kg at 14 days of age). Second, carbon tetra-
chloride (CCl4; 0.2 ml/kg, 2/week ip starting at 8 weeks of age) was 
administered for 9 or 14 weeks to develop advanced liver fibrosis. 
In animals treated with DEN as neonates, presence of liver fibrosis 
led to more than doubling (to 100%) of the liver tumor incidence 
as early as 5 months of age. This effect was associated with activa-
tion of cells with progenitor features in noncancerous liver tissue, 
including markers of replicative senescence (p16), oncofetal trans-
formation (Afp, H19, and Bex1), and increased “stemness” (Prom1 
and Epcam). In contrast, the dose of DEN used did not modify the 
extent of liver inflammation, fibrogenesis, oxidative stress, prolif-
eration, or apoptosis induced by subchronic CCl4 administration. 
This study demonstrates the potential role of liver stem-like cells 
in the mechanisms of chemical-induced, fibrosis-promoted HCC. 
We posit that the combination of genotoxic and fibrogenic insults 
is a sensible approach to model liver carcinogenesis in experimen-
tal animals. These results may contribute to identification of cir-
rhotic patients predisposed to HCC by analyzing the expression of 
hepatic progenitor cell markers in the noncancerous liver tissue.
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The incidence of liver cancer, including hepatocellular car-
cinoma (HCC), continues to increase worldwide, most promi-
nently in the developed countries in North America, Europe, 
and Oceania (Center and Jemal, 2011). Major etiological factors 
contributing to HCC are well established and include viral infec-
tions, excessive ethanol consumption, environmental carcino-
gens, and hemochromatosis (El-Serag and Rudolph, 2007; Farazi 
and DePinho, 2006). More recently, metabolic diseases related to 
insulin resistance collectively identified as nonalcoholic steato-
hepatitis have been recognized to be causally related to HCC as 
well (Della Corte and Colombo, 2012). Still, the understanding 
of HCC pathogenesis and the mechanisms of tumor development 
is incomplete (Fausto and Campbell, 2010; Vucur et al., 2010).
Animal models, most often rat or mouse, are commonly used to 
understand the molecular pathogenesis of HCC (Heindryckx et al., 
2009), as well as to test for the cancer hazard potential of chemi-
cals and drugs (Wells and Williams, 2009). Liver is the most com-
mon tissue for tumor development in experimental rodent studies 
of chronic exposure to xenobiotics (Hoenerhoff et al., 2011; Huff 
et al., 1991). However, the overwhelming majority of the positive 
(i.e., significant increases in the incidence of liver adenomas and 
carcinomas) chronic rodent cancer studies fail to produce liver 
fibrosis or cirrhosis. In cases when cirrhotic changes are observed 
in rodent liver in association with development of hepatocellular 
neoplasms (e.g., thioacetamide and N-nitrosomorpholine), high 
necrogenic doses were applied (Becker, 1983; Oh et al., 2002).
Lack of fibrosis and cirrhosis in most positive 2-year cancer 
bioassays in rodents is in stark contrast to human HCC where 
liver cirrhosis is both the most common histopathological 
feature observed in subjects with HCC and an important 
mechanism of hepatocarcinogenesis (Farazi and DePinho, 
2006). In fact, the incidence of HCC in noncirrhotic human 
livers is estimated at only 15–20% of all cases, and in the livers 
that are devoid of any signs of chronic disease, the incidence is 
even lower at about 10% (Alkofer et al., 2011). Thus, among 
many limitations, chronic rodent cancer bioassays do not 
address this key feature of human HCC.
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Although mechanistic studies of chemical carcinogenesis in 
the liver have been largely replaced in the past decade by the 
genetically modified mouse models (Lee et al., 2004), testing 
of chemicals for cancer hazard continues to be conducted in 
B6C3F1 mouse hybrid strain, rather than in genetically altered 
mouse models (Bucher, 1998). Given the importance of liver 
cirrhosis in the development of human HCC, integrative stud-
ies that evaluate the mechanisms of fibrogenesis, and how they 
relate to hepatocyte transformation and modulation of onco-
genic signaling, are most relevant to better understanding of the 
pathogenesis of human disease.
These goals can be best achieved by animal models that, as 
much as possible, mimic molecular pathogenesis of liver disease 
leading to HCC development in humans, where a combination of 
etiological factors such as genotoxic injury and advanced fibrosis 
is likely to be in play (Fausto and Campbell, 2010). Accordingly, 
this study used a well-known model of liver carcinogenesis 
induced by a single injection of a low-dose genotoxic agent 
diethylnitrosamine (DEN) into 14-day-old male mice (Druckrey 
et al., 1964; Vesselinovitch and Mihailovich, 1983). Then, repeat 
dosing of the profibrogenic agent carbon tetrachloride (CCl
4
) 
was performed, starting at 8 weeks of age for up to 14 consecu-
tive weeks. We observed that in mice initiated with DEN, chronic 
liver fibrosis led to dramatic potentiation of the liver tumor inci-
dence where 100% of the animals had developed liver tumors at 
5 months of age. In addition, we show that in DEN-treated ani-
mals, this promotional effect on liver carcinogenesis was associ-
ated with the induction of cancer stem cells in noncancerous liver 
tissue, rather than an effect on liver inflammation, fibrogenesis, 
oxidative stress, proliferation, or apoptosis.
MaTErIalS aND METHoDS
Animals and treatments. Timed pregnant B6C3F1/J mice (Jackson, Bar 
Harbor, ME) arrived about a week before delivery. Male pups were randomly 
assigned to treatment groups (Fig. 1A). Male mice were selected for these studies 
because male gender is a risk factor for human HCC (Jepsen et al., 2007). At 2 
weeks of age, mice in Groups 1 and 3 were injected ip with sterile PBS (15 µl/g) 
vehicle. At the same age, mice in Groups 2 and 4 were injected ip with DEN 
(1 mg/kg) in sterile saline (15 µl/g). Mice were maintained on animal chow with 
free access to food/water for the duration of the study. At 8 weeks of age (6 weeks 
after a single injection of DEN or vehicle as detailed above), mice in groups 1 and 
2 were injected ip 2× weekly with sterile olive oil (15 ml/kg), and mice in groups 
3 and 4 were injected ip 2× weekly with CCl
4
 (0.2 ml/kg) diluted in oil vehicle 
for up to 14 additional weeks. On the day of the last injection, mice were given 
drinking water containing bromodeoxyuridine (BrDU; 0.2 g/l; Sigma, St Louis, 
MO) for 3 days and sacrificed at the end of BrDU treatment.
Two time points were considered. Five mice in each of the four groups were 
sacrificed at 17 weeks of age (9 weeks of CCl
4
). Remaining animals were sacri-
ficed at 22 weeks of age (14 weeks of CCl
4
). Group sizes were larger (e.g., 26 ani-
mals in DEN + CCl
4
 group) for the 22 weeks of age time point to allow for more 
precise tumor incidence estimation. Body and wet liver weights were recorded, 
and blood was collected into heparin-containing syringes. All animal experiments 
were approved by the UNC Animal Care and Use Committee. Serum alanine ami-
notransferase, alkaline phosphatase, and albumin levels were determined using 
Vitro350 analyzer (Ortho-Clinical Diagnostic, Rochester, NY).
Liver histopathology. The livers were examined macroscopically for 
masses by two certified veterinary pathologists independently and in a blinded 
fashion. All liver lobes were step-sectioned at 5–7 mm to reveal macroscopi-
cally visible tumors. A section of the liver (including gross lesions) and duo-
denum was formalin-fixed and paraffin-embedded. Remaining liver tissue was 
stored at −80°C. Grossly visible tumors were separated from noncancerous 
liver tissue and frozen. Masson’s trichrome procedure was used to evaluate the 
degree of liver fibrosis with the degree of fibrosis assigned according to the fol-
lowing criteria: 0, no fibrotic changes; 1, slight fibrotic changes around the cen-
tral vein and occasionally with thin bridging fibrosis; 2, thick bridging fibrosis 
and pseudolobule formation with dissecting nodules. Histopathological evalu-
ation of the liver sections (scored using 0–3 scale), including the incidence and 
multiplicity of preneoplastic lesions (hepatocellular foci), was performed on 
the median and left liver lobes by veterinary pathologists.
Immunohistochemistry. For paraffin-embedded liver sections (5  µm 
thick), we used Dako EnVision System (Dako, Carpinteria, CA) HRP kit. All 
primary antibodies were diluted in saline containing 1% bovine serum albumin. 
The primary antibodies used in these experiments: anti-BrDU (Dako; 1:200 
dilution, 10 min), rabbit anti-4-hydroxynonenal (HNE; Alpha Diagnostics, San 
Antonio, TX; 1:200, 30 min), mouse anti-human alpha-smooth muscle actin 
(αSma; Dako; 1:100, 10 min). Slides were counterstained with filtered Mayer’s 
hematoxylin (Sigma) for 5 min. Apoptotic bodies in liver sections were detected 
by terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling 
(TUNEL) of DNA fragments using an ApopTag Peroxidase In Situ Apoptosis 
Detection Kit (Serologicals Corporation, Norcross, GA). Quantitative analysis 
was performed using Image-ProVR Plus (Media Cybernetics, Silver Spring, 
MD) at 100× magnification. For αSma and 4-HNE, five fields of noncancerous 
tissue were randomly selected to calculate percent of positively stained area. 
For BrDU and TUNEL, 10 fields were selected at random, and liver parenchy-
mal cells were counted (> 1000 cells per slide).
Frozen liver sections (10 μm) were fixed in acetone/methanol (1:1) at 4°C 





 and 0.065% sodium azide for 30 min. The following primary antibod-
ies (staining time 1 h, room temperature) were used: rat anti-F4/80 (1:200), 
rat anti-CD68 (1:2000), rat anti-CD11b (1:500) were from AbD Serotec, 
Oxford, UK, and rat anti-MHC class II (1:1000, BD Pharmingen, San Diego, 
CA). Peroxidase-conjugated secondary antibody (Nichirei, Tokyo, Japan) and 
3,3′-diaminobenzidine (Vector, Burlingame, CA) were employed for visuali-
zation. Positively stained cells (per millimeter square area) were counted in 
liver tissue, as well as in interlobular connective tissue, regions in three random 
fields using WinRoof software (Mitani, Fukui, Japan).
Quantification of genomic 8-oxo-deoxyguanine. Capillary liquid 
 chromatography tandem mass spectrometry was used for the detection of 
8-oxo-deoxyguanine (8-oxo-dG) adducts in liver DNA isolated and processed 
as detailed in the study by Powell et al. (2006).
Quantitative real-time reverse transcription PCR. RNeasy kit (Qiagen, 
Valencia, CA) was used to isolate mRNA from frozen liver. RNA concentration 
and quality were assessed using ND-1000 (NanoDrop, Wilmington, DE) and 
2100 Bioanalyzer (Agilent, Santa Clara, CA), respectively. Reverse transcrip-
tion was carried out using High Capacity cDNA RT kit (Applied Biosystems, 
Foster City, CA). Each sample was analyzed in duplicate using the Light-
Cycler 480 (Roche, Indianapolis, IN). Primers were obtained from Applied 
Biosystems and are listed in Supplementary table 1. The relative amount of 
target gene mRNAs was normalized to internal control gene Gusb.
Statistical analyses. Statistical significance was determined using 
GraphPad (San Diego, CA) Prism5. Quantitative values are expressed as mean 
± SD unless otherwise noted. Statistical significance was evaluated using one-
way ANOVA within each time point followed by the Bonferroni’s post hoc test. 
Statistical significance is indicated at any level below p < 0.05.
rESulTS
We first studied whether chronic treatment with a 
profibrogenic agent (CCl
4
) affects carcinogenesis caused by 
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DEN, a genotoxic agent. Animals in all four groups (Fig. 1A) 
survived until sacrifice at 17 (n  =  5/group) or 22 weeks of 
age (n  =  7–26/group). Serum markers of liver injury were 
evaluated (Table 1), and livers were examined both macro- and 
microscopically for presence of pre- and neoplastic lesions, as 
well as signs of tissue injury (Figs. 1B and C, Table 2). No liver 
injury or pre- or neoplastic lesions were found in the vehicle 
group at both time points.
In animals that received only DEN (1 mg/kg), a single non-
necrogenic dose to study initiation phase of carcinogenesis, no 
abnormalities in serum or liver markers of injury, or gross liver 
pathology, were observed (Tables 1 and 2, Fig. 1B); however, 
a marked increase in the incidence of liver foci (above 80% at 
both time points) and liver adenomas (10% only at 22 week of 
age group) was detected (Fig. 1C).
In CCl
4
 (0.2 ml/kg) only–treated groups, a significant 
increase in liver to body weight ratio (Table  1) and progres-
sively worsening (with time) changes in liver histopathology 
and serum markers (Tables 1 and 2) were detected. Specifically, 
single cell necrosis, ballooning degeneration of hepatocytes, 
FIg. 1. Experimental design, gross liver pathology, incidence of liver tumors, liver cell proliferation, and apoptosis. (A) Study design consisted of four groups 
(see Materials and Methods section) and two time points (17 and 22 weeks of age). (B) Representative photographs of the livers from the animals in each group 
at 22 weeks of age. (C) Incidence of the neoplastic (adenomas and carcinomas) and preneoplastic (foci) liver lesions. Mean ± SD values for percent BrDU- (D) 
or TUNEL- (E) positive nuclei for five randomly selected fields (devoid of foci, adenomas, or carcinomas) at ×200 are shown (n = 4–8 animals/group). Asterisks 
denote statistical significance from other groups (as indicated by the lines and brackets) at p < 0.05.
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and steatosis were observed in central and midlobular regions, 
often associated with fibrosis and inflammatory cell infiltration. 
Nonnecrotic hepatocytes exhibited hypertrophy with anisonu-
cleosis. At 17 weeks of age group, no foci, adenomas, or carci-
nomas were observed. Liver foci and adenomas were found in 
12.5% of mice at 22 weeks of age group, whereas the incidence 
of carcinomas was 25% (Fig. 1C).
Most pronounced pathological observations were detected in 
the livers of animals that were first initiated with DEN and then 
treated with repeat injections of CCl
4
. In 17-week-old animals, an 
increase in relative liver weight and mild liver histopathological 
changes were observed (Tables 1 and 2). All animals in this group 
had already developed liver foci, whereas 40 and 20% of animals 
manifested with liver adenomas and carcinomas, respectively 
(Fig.  1C). In 22-week-old animals, all animals in this group 
exhibited increases in relative liver weight and marked elevation 
of serum and histopathological markers of liver injury (Tables 1 
and 2). All animals developed liver adenomas, and 50% also had 
liver carcinomas (Fig. 1C). It is of note that in both CCl
4
-treated 
groups, the severity of liver injury (single cell necrosis, ballooning 
degeneration and hypertrophy of hepatocytes, and fibrosis with 
inflammatory cells infiltration) in noncancerous tissue was of 
similar grade regardless of whether the animals were initiated 
with DEN or not (Tables 1 and 2).
It is well established that continuous exposure to CCl
4
 leads 
to the development of severe hepatic fibrosis and compensatory 
cell proliferation (Stowell et al., 1951). Thus, we determined 
whether the marked increase in liver tumor incidence in DEN 
+ CCl
4
 group may be due to combined effects on hepatocyte 
turnover or liver fibrosis. Cell proliferation, as assessed by 
BrDU labeling index (Fig. 1D) and mitotic figures (Table 2), 
was progressively elevated in animals that received CCl
4
, inde-
pendent of prior initiation with DEN. Apoptosis, as measured 
by TUNEL-positive nuclei (Fig. 1E), was elevated up to three-
fold, but there was no difference between CCl
4
 and DEN + CCl
4
 
groups at either time point. Liver fibrosis was assessed using 
Masson’s trichrome staining (Fig.  2A), immunostaining for 
αSma, and expression of Timp1 (Fig. 2B). Clear evidence of 
progressively worsening liver fibrosis was observed in CCl
4
-
treated groups, whereas treatment with DEN had no additive 
effect.
Recent studies have identified the key role of chemokines and 
chemokine receptors in promotion of hepatic fibrosis, includ-
ing that caused by CCl
4
 (Aoyama et al., 2010; Seki et al., 2009). 
Accordingly, we have evaluated the changes in expression of 
key profibrogenic chemokines and their receptors in our model 
(Fig. 2C). Expression of Ccr1, Ccr5, Ccl3, and Cx3cr1 was mark-
edly elevated in 22-week-old mice treated with CCl
4
, independent 
of prior initiation with DEN. Significant changes in expression of 
some chemokines were also evident in 17-week-old animals.
Both CCl
4
 and DEN are known to promote liver inflammation 
and oxidative stress, which are potential mechanisms involved 
in hepatic carcinogenesis. Thus, we evaluated whether these 
mechanisms may be responsible for the difference in liver tumor 
incidence between CCl
4
 and DEN + CCl
4
 groups. We performed 
detailed profiling of the populations of inflammatory cells in 
liver tissue and fibrotic areas in mice that were 22 weeks of age. 
In the liver tissue of control mice, F4/80-positive macrophages 
were predominant (Figs. 3A and C). These were located mainly 
in the sinusoids and exhibited cytoplasmic morphology charac-
teristic of Kupffer cells. CD68-positive macrophages were the 
second most frequent inflammatory cell in the liver tissue, and 
the distribution pattern was similar to that of F4/80-positive 
macrophages. CD11b-positive small round cells with inverted 
vesicular nuclei and monocytic morphology were few in the 
normal tissue. There were some MHC2-positive macrophages 
in the sinusoids of liver tissue. In DEN-initiated mice, the num-
ber of F4/80- and CD68-positive sinusoidal macrophages was 
significantly increased compared with vehicle group. A  much 
greater number of inflammatory cells of all types was present in 
nonparenchymal liver tissue (Figs. 3B and C), the predominant 
population being MHC2-positive macrophages with dendritic 
morphology that were located around portal blood vessels. The 
number of macrophages with all four immunophenotypes was 
significantly increased in the fibrotic lesions of CCl
4
 and DEN + 
CCl
4
 groups compared with vehicle and DEN-only groups; how-
ever, there was no significant difference between CCl
4
 and DEN 
+ CCl
4
 groups. The macrophages in the fibrotic lesions varied in 
morphology (Fig. 3C), suggesting a heterogeneous population.
In all CCl
4
-treated animals at both time points, the histo-
pathological analysis of liver (Table 2) revealed progressively 
worsening anisonucleosis, a morphological manifestation 
TaBlE 1










Age at sacrifice (weeks) 17 17 22 22
Number of animals/group  5  5 7 20 8 26
Serum albumin (g/dl) 2.5 ± 0.1 2.5 ± 0.1 2.7 ± 0.1 2.4 ± 0.1 2.6 ± 0.1 2.6 ± 0.1 2.9 ± 0.1 3.4 ± 0.3a,b
Serum alanine aminotransferase (U/l) 88 ± 23 43 ± 3 84 ± 2 74 ± 5 48 ± 5 52 ± 4 202 ± 12a,b 185 ± 20a,b
Serum alkaline phosphatase (U/l) 72 ± 4 72 ± 6 66 ± 5 67 ± 4 44 ± 7 55 ± 7 79 ± 8a,b 72 ± 4a,b
Relative liver weight (%) 4.6 ± 0.1 4.8 ± 0.2 5.3 ± 0.1a 5.2 ± 0.1a 5.2 ± 0.2 4.9 ± 0.2 6.4 ± 0.2a,b 7.2 ± 0.3a,b,c
Note. Mean ± SD values are shown.
aIndicates statistical significance of the differences (p < 0.05) from the corresponding (with respect to the time point) PBS-treated groups.
bIndicates statistical significance of the differences (p < 0.05) from the corresponding (with respect to the time point) DEN-treated groups.
cIndicates statistical significance of the differences (p < 0.05) from the corresponding (with respect to the time point) CCl
4
-treated groups.
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of nuclear injury characterized by variation in the size of the 
hepatocyte nuclei, an observation that has been associated 
with hepatic oxidative stress (Guzman et  al., 2011). In addi-
tion, accumulation of lipofuscin granules, lipid-containing 
remnants of lysosomes considered to be a hallmark of lipid 
peroxidation in the liver, was also observed in these groups. 
DEN treatment had no effect on these phenotypes. To further 
evaluate the degree of oxidative stress (Table 3), we assessed 
lipid peroxidation through immunohistochemical detection of 
4-HNE-adducted proteins, DNA oxidation from the number of 
8-oxo-dG adducts, and expression of several key base-excision 
DNA repair genes (Rusyn et al., 2004). A significant increase 
in hepatic lipid peroxidation was observed in CCl
4
-treated 
groups at both time points. DEN + CCl
4
 groups had higher lev-
els of 4-HNE positive staining than those in CCl
4
-only groups, 
albeit the difference was not significant (p > 0.05). No change 
in the number of 8-oxo-dG adducts was observed. Expression 
of Polβ was lower in CCl
4
 and DEN + CCl
4
 groups in 17- and 
22-week-old animals compared with corresponding control 
groups. Expression of Ogg1 was decreased only in DEN + CCl
4
 
group in 22-week-old animals.
A dramatic increase in cell proliferation was observed in 
livers of CCl
4
- and DEN + CCl
4
–treated mice (Fig. 1D). Recent 
studies suggest that high proliferation due to hepatitis and 
cirrhosis leads to hepatocyte senescence and activation of hepatic 
progenitor cells, which in turn heightens the risk of neoplastic 
transformation (Oishi and Wang, 2011). The concept of liver 
cancer stem cells has gathered significant attention, and most 
of experimental evidence suggests that these cells derive from 
hepatic progenitor cells (Wang and Jacob, 2011). Accordingly, we 
have investigated the markers of oncofetal liver transformation 
and cancer stem cells (Fig. 4). Upregulation of Afp, H19, and 
Bex1, fetal stage–specific genes, is known to be present in liver 
tumors but has also been observed in noncancerous liver tissue 
(Inokuchi et  al., 2010). In our study, increased expression of 
these genes was observed in noncancerous liver tissue in both 
TaBlE 2










Age at sacrifice (weeks) 17 17 22 22
Number of animals/group  5  5 7 20 8 26
Single cell necrosisa
1+ 5 (19)
2+ 6 (75) 7 (27)
3+ 1 (13) 6 (23)
Total 7 (88) 18 (69)
Fibrosis with mononuclear cells infiltration
1+ 5 (100) 5 (100)
2+ 8 (100) 26 (100)
3+
Total 5 (100) 5 (100) 8 (100) 26 (100)
Hypertrophy
1+ 5 (100) 5 (100)
2+ 8 (100) 26 (100)
3+
Total 5 (100) 5 (100) 8 (100) 26 (100)
Increased mitosis
1+ 5 (19)
2+ 8 (100) 21 (81)
3+
Total 8 (100) 26 (100)
Anisonucleosis
1+ 5 (100) 5 (100)
2+ 25 (96)
3+ 8 (100) 1 (4)
Total 5 (100) 5 (100) 8 (100) 26 (100)
Lipofuscin deposition
1+ 5 (100) 5 (100)
2+ 8 (100) 26 (100)
3+
Total 5 (100) 5 (100) 8 (100) 26 (100)
Steatosis
1+ 1 (20) 2 (8)
2+ 4 (50) 21 (80)
3+ 2 (25)
Total 1 (20) 6 (75) 23 (88)
Note. aNumber of animals for each grade (% of total).
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CCl
4
-treated groups as early as 17 weeks of age. Notably, 
expression of these genes was significantly (two- to fivefold) 
greater in DEN + CCl
4
 groups compared with CCl
4
-only groups. 
To determine whether a decline in regenerative potential, 
indicative of hepatocyte senescence, is observed, we evaluated 
expression of p16, a cell-cycle inhibitor that is regarded as a key 
regulator of entry of cells into S-phase (Krishnamurthy et al., 
2004). Indeed, expression of p16 was increased in DEN + CCl
4
 
group at both 17 and 22 weeks of age and significantly different 
from that in other groups. To determine whether expression of 
cancer stem cell markers is associated with higher liver tumor 
incidence in this model, we considered Prom1 (CD133; Ma 
et al., 2007) and Epcam (Yamashita et al., 2009). Although no 
effect was observed in 17-week-old mice (all groups), expression 
of both genes was significantly higher (2- to 2.5-fold) in DEN 
+ CCl
4
 group compared with CCl
4
-only and other groups at 22 
weeks of age.
DISCuSSIoN
Our current understanding of cancer etiology and 
pathogenesis in general, and liver carcinogenesis in particular, 
is based largely on the multistage model of clonal evolution 
FIg. 2. Liver fibrogenesis markers. (A) Representative Mason’s trichrome stain sections (×100) from animals at 22 weeks of age. (B) Immunostaining of 
αSMA in liver in five randomly selected fields at ×200; liver expression of Timp1 (relative to levels in PBS group at each time point). Treatment groups are 
denoted as indicated in the graphical legend. Mean ± SD values are shown, n = 4–8 animals/group. (C) Liver expression of profibrogenic inflammatory cytokines. 
Treatment groups are denoted as indicated in the legend in panel B. Mean ± SD values are shown, n = 5 animals per group. Asterisks denote statistical significance 
from other groups (as indicated by the lines and brackets) at p < 0.05.
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(Pitot, 1977) and the concepts of the “mutator phenotype” 
(Loeb, 2001) and “hallmarks of cancer” (Hanahan and 
Weinberg, 2011). Much is known about the histopathological 
progression, molecular features, and genetic diversity of liver 
tumors (Farazi and DePinho, 2006; Nault and Zucman-Rossi, 
2011). The role of cancer stem cells in tumor development has 
been also proposed (Marquardt and Thorgeirsson, 2010; Wang 
and Jacob, 2011). The field of experimental liver cancer research 
has generated much observational and molecular evidence for 
the above-mentioned conceptual models, including data on 
the modifying effects of various lifestyle factors (e.g., alcohol 
drinking), dietary exposures (e.g., aflatoxins), chronic viral 
infections (e.g., hepatitis viruses B and C), and advanced fibrosis 




 is a well-known 
“promoting” agent in rodent hepatocarcinogenesis, with most 
of the data demonstrating its ability to increase the incidence 
of liver tumors following initiation with a genotoxic chemical 
being published 20 or more years ago (Dragani et al., 1986).
Our study generated novel results as it allows better under-
standing of why patients with liver cirrhosis and etiological fac-
tors that may promote DNA damage (e.g., exposure to genotoxic 
agents, viral hepatitis, etc.) are more prone to development of 
HCC than patients with cirrhosis alone (El-Serag and Rudolph, 
2007). Indeed, using a mouse model of HCC induced by a sin-
gle injection of a genotoxic chemical followed by advanced 
liver fibrosis, we performed a comprehensive evaluation of the 
well-accepted mechanisms of liver carcinogenesis, such as cell 
proliferation, apoptosis, fibrogenesis, necrosis, inflammation, 
FIg. 3. Macrophage subpopulations in liver tissue and fibrotic areas. Immunohistochemical analysis of macrophage markers F4/80, CD68, CD11b, and 
MHC2 was conducted at 22 weeks of age. Image analysis is presented for nonfibrotic/noncancerous liver tissue (A) or fibrotic and perivascular regions (B). Mean 
± SD values are shown, n = 3 animals/group. Asterisks denote statistical significance from other groups (as indicated by the lines and brackets) at p < 0.05. Panel 
C shows representative microphotographs at ×100.
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and oxidative stress. Although a clear increase in these molecu-
lar mechanisms of liver cancer was observed in animals treated 
with CCl
4
, the magnitude of the observed effects was largely 
unrelated to tumor incidence and not affected by DEN. This 
suggests that other more subtle molecular events may have a 
pronounced overall impact on tumor incidence, especially 
when coexposure to multiple agents takes place.
One mechanism that could be responsible for the observed 
acceleration of HCC development in this model is the poten-
tial for CCl
4
 to cause DNA damage. It cannot be unequivocally 
concluded that CCl
4
 is only fibrogenic and not genotoxic in this 
model. However, we reason that there is only a minor, if any, 
role of potential oxidative stress–derived DNA damage in the 
observed cocarcinogenesis effect. CCl
4
 is not a directly muta-
genic agent, but it may contribute to DNA damage and muta-
tions through indirect mechanisms resulting from oxidative and 
lipid peroxidative damage or damage occurring during necrosis 
or apoptosis (Eastmond, 2008). The key events in this process 
are expected to occur in a nonlinear fashion, and it is known that 
the relationship between CCl
4
 dose and carcinogenic response 
in the liver is nonlinear with a steep dose response (Nagano 
et al., 2007). We have used low doses of CCl4 compared with 
other published studies that evaluated subchronic liver toxicity 
in rodents using ip injections. For example, a dose that is 2.5-
times higher (0.5 ml/kg) was shown to only marginally affect 
liver oxidant/antioxidant balance (Cabré et  al., 2000). In our 
study, neither hepatotoxicity was observed following 9 weeks 
of CCl
4
 administration (no elevation of serum enzymes or signs 
of liver necrosis) nor was there evidence for macrophage infil-
tration in nonfibrotic liver tissue (by immunohistochemical 
detection). Likewise, although lipid peroxidation was detected 
in CCl
4
-treated groups, compared with animals receiving oil 
injections, this effect was not associated with an increase in 
oxidative DNA damage (i.e., 8-oxo-dG adducts), and it was 
not concordant with the marked differences in tumor incidence 
between groups. Still, extensive genetic analysis (e.g., com-
parative genomic hybridization and exome sequencing) of the 
tumors in each group may be needed to assess whether CCl
4
 
acts as a genotoxic agent or not in the present model.
The hierarchical cancer model posits that another key 
event in liver carcinogenesis that may be responsible for the 
observed differences is formation of cancer stem cells that 
occupy the apex of tumor formation and are responsible for 
tumor initiation, growth, and metastases (Marquardt and 
Thorgeirsson, 2010). Although the mechanisms of cancer stem 
cell involvement in the initiation and progression of HCC are 
a subject of intense research and debate, most accept their key 
role in HCC (Ji and Wang, 2012; Lee et al., 2012; Majumdar 
et al., 2012). Few studies, however, have evaluated cancer stem 
cells in the noncancerous liver tissue. In our study, the marked 
effect of liver fibrosis on genotoxic agent–initiated liver was 
associated with replicative senescence (e.g., overexpression of 
p16), oncofetal transformation (e.g., increased expression of 
Afp, H19, and Bex1), and increased “stemness” (e.g., increased 
expression of Prom1 and Epcam) of the noncancerous liver 
tissue. Indeed, all of these pathways have been linked to cancer 
stem cell–dependent events in hepatocarcinogenesis (Oishi and 
Wang, 2011; Wang and Jacob, 2011).
Expression of p16, a cell-cycle inhibitor that prevents 
CDK4/6-dependent phosphorylation of retinoblastoma protein 
that is controlling the entry of cells into S-phase (Chazal et al., 
2002), is delicately balanced in mammalian tissues. Because of 
its role in proliferation, p16 is a molecular biomarker of cellular 
senescence, with its expression markedly increasing with age 
(Krishnamurthy et al., 2004). Interestingly, DNA damage from 
chemicals, UV or radiation, and telomere dysfunction and oxi-
dative stress are known to result in increased expression of p16 
(Li et al., 2011), which, in turn, triggers hepatocyte senescence 
and reactivation of hepatic progenitor cells (Yang et al., 2004).
The increased stemness of the noncancerous liver tissue in 
CCl
4
-treated animals is in line with recent evidence that there 
is an association between fibrosis and liver progenitor cell acti-
vation (Greenbaum and Wells, 2011). Prom1 was significantly 
induced in noncancerous and tumor samples in mice treated 
with CCl
4
 for 15 weeks (Fujii et al., 2010). Although the mech-
anisms that link progenitor cells and liver fibrosis have not been 
elucidated fully, Hedgehog, Wnt, and Notch have been identi-
fied as common pathways. Importantly, our observation of a 
TaBlE 3 










Age at sacrifice (weeks) 17 17 22 22
4-HNE positive area (%) 4.1 ± 1.7 5.8 ± 3.5 19 ± 8a,b 30 ± 6a,b 5.4 ± 2.3 10 ± 3 13 ± 7a   26 ± 11a,b
8-oxo-dG/106 dG 1.6 ± 0.5 1.3 ± 0.2 2.3 ± 1.1 2.1 ± 0.9 1.2 ± 0.2 1.0 ± 0.3 1.2 ± 0.4 1.4 ± 0.2
Ogg1 mRNAc 100 ± 21 92 ± 8 85 ± 13 89 ± 10 100 ± 32 83 ± 9 65 ± 20 53 ± 9b
Apex mRNAc 100 ± 22 88 ± 14 160 ± 97 140 ± 25 100 ± 17 126 ± 33 82 ± 30 84 ± 34
Polβ mRNAc 100 ± 10 84 ± 11 48 ± 26a 36 ± 8b 100 ± 25 110 ± 14 48 ± 11a 43 ± 28b
Notes. Mean ± SD values are shown, n = 4–8 animals/group.
aStatistical significance (p < 0.05) from corresponding time point PBS groups is indicated.
bStatistical significance (p < 0.05) from corresponding time point DEN groups is indicated.
cLiver expression levels of base-excision DNA repair genes Ogg1 (8-oxoguanine DNA-glycosylase 1), Apex (apurinic/apyrimidinic endonuclease 1), and Polβ 
(polymerase (DNA directed), beta) are expressed as ratio to corresponding time point’s PBS group.
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much greater incidence of liver tumors in DEN + CCl
4
 group, 
compared with that in CCl
4
-alone group, suggests thatalthough 
fibrosis and hepatocarcinogenesis may share similar molecular 
pathways that result from adaptive responses during chronic 
liver injury, presence of DNA mutations, as a result of expo-
sure to genotoxic agents, may tip the balance even more toward 
carcinogenesis. This concept is supported by a recent study that 
showed that a connection of differentiation and DNA damage 
responses in liver stem or progenitor cells allows for the forma-
tion of tumor-initiating cells (Kossatz et al., 2010). Increased 
expression of oncofetal genes in animals with the greatest inci-
dence of liver tumors is another line of evidence that suggests 
that tissue regeneration pathways and carcinogenesis are not 
the same as several of marker genes tested are not upregulated 
in regenerating liver (Graveel et  al., 2001). Reactivation of 
oncofetal genes is a common feature in both human HCC and 
in murine liver cancer induced by DEN (Braeuning et al., 2006; 
Graveel et al., 2001).
While we posit that markers of stemness in the noncan-
cerous liver tissue are markers of early carcinogenesis, an 
additional explanation is that they may be a sign of poor 
hepatocyte regeneration. We (Sancho-Bru et al., 2012) and oth-
ers (Katoonizadeh et al., 2006) have demonstrated that hepatic 
progenitor cells accumulate in patients with advanced liver cir-
rhosis and are associated with a poor outcome. The accumula-
tion of these cells reflects poor hepatic regeneration and may 
be also linked to increased carcinogenesis. Thus, the results of 
this study may suggest that expression of hepatic progenitor 
cell markers in the noncancerous liver tissue could be explored 
in additional studies as a biomarker of predisposition for the 
development of HCC in cirrhotic subjects.
Another important outcome of this study is the model itself 
whereby it features the hallmarks of human liver cancer: 
chronic liver injury, inflammation, and fibrosis. This experi-
mental design, incorporating chronic exposure to a relatively 
low dose of CCl
4
, compared with most other studies of CCl
4
-
induced fibrosis or hepatocarcinogenesis (Dragani et al., 1986; 
Fujii et al., 2010), with an environmental chemical carcinogen 
may provide a useful model to further investigate the contribu-
tion of inflammation and fibrosis to liver cancer. Such “fibrotic” 
liver murine model may not only be more human relevant but 
also faster (HCCs and adenomas develop in as little as 17 
FIg. 4. Markers of oncofetal transformation, senescence, and cancer stem cells. Liver gene expression of the genes indicated on the y-axis of each graph was 
evaluated as detailed in Materials and Methods section (see Supplementary table 1 for gene names and primers). Treatment groups are denoted as indicated in the 
legend in top left panel. Mean ± SD values are shown, n = 5 animals/group. Asterisks denote statistical significance from other groups (as indicated by the lines 
and brackets) at p < 0.05.
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weeks of age) than a traditional 2-year rodent cancer bioassay 
used widely to ascribe cancer hazard to chemicals and drugs. 
As much research effort and regulatory pressure is directed 
at the development of short-term transgenic mouse assays to 
supplant the need for most 2-year bioassays (Jacobson-Kram, 
2010), the model characterized in our study may represent a 
more clinically relevant scenario. Indeed, as it is well recog-
nized that most of the human HCCs are a result of multiple 
etiologies and require liver cirrhosis (Alkofer et al., 2011), the 
model described here is more likely, compared with several 
transgenic models currently being evaluated (Bucher, 1998), to 
be able to recapitulate fibrotic phenotype seen in humans.
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